Combination of TRAP1 and ERCC1 Expression Predicts Clinical Outcomes in Metastatic Colorectal Cancer Treated with Oxaliplatin/5-Fluorouracil
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
PurposeThe novel heat shock protein tumor necrosis factor receptor-associated protein 1(TRAP1) is associated with multidrug resistance in colorectal cancer (CRC) cells invitro. Excision repair cross-complementation group 1 (ERCC1) expression levels intumor tissues also predict clinical outcomes in metastatic CRC patients receivingcombination oxaliplatin and 5-fluorouracil treatment. We investigated whether TRAP1and ERCC1 protein expression by immunohistochemistry predict clinical outcomes inCRC patients. Materials and MethodsThe study population consisted of 56 patients with metastatic CRC who receivedfirst-line oxaliplatin/5-fluorouracil therapy. Clinical response and overall survival (OS)by levels of the markers TRAP1 and ERCC1 were evaluated. ResultsThe rates of TRAP1 and ERCC1 expression were 21% and 52%, respectively. Patientsnegative for ERCC1 expression showed a tendency to respond to chemotherapy(p=0.066). Median OS was significantly longer in patients negative for TRAP1 thanthose positive for TRAP1 (p=0.023). Patients negative for ERCC1 expression also hada better OS than those positive for ERCC1 (p=0.021). The median OS was 30.9months for patients negative for TRAP1 and ERCC1 compared to 13.2 months forthose positive for TRAP1 and/or positive for ERCC1 expression (p=0.006). Thecombination of TRAP1 and ERCC1 expression was significantly associated with theresponse to chemotherapy (p=0.046) and independently predicted median OS inmultivariate analysis (hazard ratio, 2.98; 95% confidence interval, 1.18 to 7.49). ConclusionThe present study demonstrates that the combination of TRAP1 and ERCC1 expressionpredicts the survival of metastatic CRC patients who were treated with oxaliplatin/5-fluorouracil.
Abstract
PurposeThe novel heat shock protein tumor necrosis factor receptor-associated protein 1(TRAP1) is associated with multidrug resistance in colorectal cancer (CRC) cells invitro. Excision repair cross-complementation group 1 (ERCC1) expression levels intumor tissues also predict clinical outcomes in metastatic CRC patients receivingcombination oxaliplatin and 5-fluorouracil treatment. We investigated whether TRAP1and ERCC1 protein expression by immunohistochemistry predict clinical outcomes inCRC patients. Materials and MethodsThe study population consisted of 56 patients with metastatic CRC who receivedfirst-line oxaliplatin/5-fluorouracil therapy. Clinical response and overall survival (OS)by levels of the markers TRAP1 and ERCC1 were evaluated. ResultsThe rates of TRAP1 and ERCC1 expression were 21% and 52%, respectively. Patientsnegative for ERCC1 expression showed a tendency to respond to chemotherapy(p=0.066). Median OS was significantly longer in patients negative for TRAP1 thanthose positive for TRAP1 (p=0.023). Patients negative for ERCC1 expression also hada better OS than those positive for ERCC1 (p=0.021). The median OS was 30.9months for patients negative for TRAP1 and ERCC1 compared to 13.2 months forthose positive for TRAP1 and/or positive for ERCC1 expression (p=0.006). Thecombination of TRAP1 and ERCC1 expression was significantly associated with theresponse to chemotherapy (p=0.046) and independently predicted median OS inmultivariate analysis (hazard ratio, 2.98; 95% confidence interval, 1.18 to 7.49). ConclusionThe present study demonstrates that the combination of TRAP1 and ERCC1 expressionpredicts the survival of metastatic CRC patients who were treated with oxaliplatin/5-fluorouracil.
참고문헌 (25)
- Jemal A, "Global cancer statistics", CA Cancer J Clin, 61, pp.69~90 (2011)
- Felts SJ, "The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties", J Biol Chem, 275, pp.3305~3312 (2000)
- Kang BH, "Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network", Cell, 131, pp.257~270 (2007)
- Hua G, "Heat shock protein 75(TRAP1)antagonizes reactive oxygen species generation and protects cells from granzyme M-mediated apoptosis", J Biol Chem, 282, pp.20553~20560 (2007)
- Montesano Gesualdi N, "Tumor necrosis factor-associated protein 1(TRAP-1)protects cells from oxidative stress and apoptosis", Stress, 10, pp.342~350 (2007)
- Costantino E, "TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells", Cancer Lett, 279, pp.39~46 (2009)
- Martin LP, "Platinum resistance : the role of DNA repair pathways", Clin Cancer Res, 14, pp.1291~1295 (2008)
- Shirota Y, "ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy", J Clin Oncol, 19, pp.4298~4304 (2001)
- Kim MK, "ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer", Eur J Cancer, 44, pp.54~60 (2008)
- Leav I, "Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer", Am J Pathol, 176, pp.393~401 (2010)
- Kang BH, "Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer", Clin Cancer Res, 16, pp.4779~4788 (2010)
- Kang BH, "Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90", J Clin Invest, 119, pp.454~464 (2009)
- Liu D, "Tumor necrosis factor receptor-associated protein 1(TRAP1)regulates genes involved in cell cycle and metastases", Cancer Lett, 296, pp.194~205 (2010)
- Arnould S, "Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines", Eur J Cancer, 39, pp.112~119 (2003)
- Kim SH, "Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU", oxaliplatin chemotherapy in advanced colorectal cancer, 2009, pp.32, 38~43
- Koopman M, "Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study", Eur J Cancer, 45, pp.1999~2006 (2009)
- Braun MS, "Predictive biomarkers of chemotherapy efficacy in colorectal cancer : results from the UK MRC FOCUS trial", J Clin Oncol, 26, pp.2690~2698 (2008)
- Yin M, "ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer : a systemic review and meta-analysis", Clin Cancer Res, 17, pp.1632~1640 (2011)
- Vallbohmer D, "Molecular determinants of irinotecan efficacy", Int J Cancer, 119, pp.2435~2442 (2006)
- Holm B, "Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine", J Clin Oncol, 27, pp.4254~4259 (2009)
- Zheng Z, "DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer", N Engl J Med, 356, pp.800~808 (2007)
- Lord RV, "Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer", Clin Cancer Res, 8, pp.2286~2291 (2002)
- Qiu LX, "Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: evidence from 24 studies", Int J Cancer, 123, pp.2384~2389 (2008)
- Popat S, "Thymidylate synthase expression and prognosis in colorectal cancer : a systematic review and meta-analysis", J Clin Oncol, 22, pp.529~536 (2004)
- Kwon HC, "Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil", oxaliplatin chemotherapy in advanced gastric cancer, 2007, pp.18, 504~509